Brind.
  1. FDA approval of LUMRYZ™ is contingent on sale terms, with Alkermes proposed as the buyer of Avadel Pharmaceuticals.

Alkermes is integrating Avadel into its operations while discussing differentiation within the orexin agonist class.

1 report, 1 independent Updated Jun 10
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Alkermes is integrating Avadel into its operations while discussing differentiation within the orexin agonist class.

Who's involved

What this event is mainly about
Alkermes

Keep exploring

Part of

FDA approval of LUMRYZ™ is contingent on sale terms, with Alkermes proposed as the buyer of Avadel Pharmaceuticals. All 2 developments

The entities involved

Coverage

Newest first; wire copies grouped